A randomized trial of brimonidine versus timolol in preserving visual function: Results from the low-pressure glaucoma treatment study

American Journal of Ophthalmology

Volumn 151, Issue 4, 2011, Pages 671-681

  Krupin, Theodore ^a,b,g   Liebmann, Jeffrey M ^c   Greenfield, David S ^d   Ritch, Robert ^c,e   Gardiner, Stuart ^f  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Chicago Center for Vision Research   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NEW YORK EYE AND EAR INFIRMARY   (United States)

^e UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g DEVERS EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; DOUBLE BLIND PROCEDURE; EYE ALLERGY; FEMALE; FOLLOW UP; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LOW PRESSURE GLAUCOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VISUAL FIELD;

ADMINISTRATION, TOPICAL; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GONIOSCOPY; HUMANS; INTRAOCULAR PRESSURE; LOW TENSION GLAUCOMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; QUINOXALINES; TIMOLOL; TONOMETRY, OCULAR; TREATMENT OUTCOME; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 79952984499     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2010.09.026     Document Type: Article

References (59)

1. L.A. Kerrigan-Baumrind, H.A. Quigley, M.E. Pease, D.F. Kerrigan, and R.S. Mitchell Number of ganglion cells in glaucoma eyes compared with threshold visual field tests in the same persons Invest Ophthalmol Vis Sci 41 3 2000 741 748 (Pubitemid 30158884)
2. R.N. Weinreb, and P.T. Khaw Primary open-angle glaucoma Lancet 363 9422 2004 1711 1720 (Pubitemid 38670330)
3. nd ed. 1996 Mosby - Year Book, Inc St.Louis 769 797
4. A. Sommer, J.M. Tielsch, and J. Katz Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans The Baltimore Eye Survey Arch Ophthalmol 109 8 1991 1090 1095
5. B.E. Klein, R. Klein, and W.E. Sponsel Prevalence of glaucoma The Beaver Dam Eye Study Ophthalmology 99 10 1992 1499 1504
6. A. Heijl, M.C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, and M. Hussein Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial Arch Ophthalmol 120 10 2002 1268 1279 (Pubitemid 36105431)
7. M.A. Kass, D.K. Heuer, and E.J. Higginbotham The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma Arch Ophthalmol 120 6 2002 701 713 (Pubitemid 34620348)
8. The AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS). 7: The relationship between control of intraocular pressure and visual field deterioration Am J Ophthalmol 130 4 2000 429 440
9. P.R. Lichter, D.C. Musch, and B.W. Gillespie Interim clinical outcomes in the Collaborative Initial Treatment Study comparing initial treatment randomized to medications or surgery Ophthalmology 108 11 2001 1943 1953 (Pubitemid 33032760)
10. Collaborative Normal-tension Study Group The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma Am J Ophthalmol 126 4 1998 498 505
11. Collaborative Normal-tension Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures Am J Ophthalmol 126 4 1998 487 497
12. M. Saylor, L.K. McLoon, A.R. Harrison, and M.S. Lee Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: An evidence-based review Arch Ophthalmol 127 4 2009 402 406
13. L.J. Katz Brimonidine Study Group Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients Am J Ophthalmol 127 1 1999 20 26 (Pubitemid 29036611)
14. S. Melamed, R. David Brimonidine Study Group II Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results Clin Ther 22 1 2000 103 111 (Pubitemid 30091427)
15. T. Krupin, J.M. Liebmann, and D.S. Greenfield The Low-pressure Glaucoma Treatment Study (LoGTS): study design and baseline characteristics of enrolled patients Ophthalmology 112 3 2005 376 385 (Pubitemid 40312487)
16. R.P. LeBlanc Brimonidine Study Group 2 Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension Ophthalmology 105 10 1998 1960 1967
17. B.N. Noureddin, D. Poinoosawmy, F.W. Fietzke, and R.A. Hitchings Regression analysis of visual field progression in low tension glaucoma Br J Ophthalmol 75 8 1991 493 495
18. J. Katz, N. Congdon, and D.S. Friedman Methodological variations in estimating apparent progressive visual field loss in clinical trials of glaucoma treatment Arch Ophthalmol 117 9 1999 1137 1142 (Pubitemid 29428821)
19. B. Bengtsson, A. Lindgren, A. Heijl, G. Lindgren, P. Asman, and M. Patella Perimetric probability maps to separate change caused by glaucoma from that caused by cataract Acta Ophthalmol Scand 75 2 1997 184 188 (Pubitemid 27249867)
20. M.C. Leske, A. Heijl, L. Hyman, B. Bengtsson Early Manifest Glaucoma Trial Group Early Manifest Glaucoma Trial: design and baseline data Ophthalmology 106 11 1999 2144 2153 (Pubitemid 30194238)
21. S.K. Gardiner, and D.P. Crabb Examination of different pointwise linear regression methods for determining visual field progression Invest Ophthalmol Vis Sci 43 5 2002 1400 1407 (Pubitemid 34462637)
22. S.K. Gardiner, D.P. Crabb, F.W. Fietzke, and R.A. Hitchings Reducing noise in suspected glaucomatous visual fields by using a new spatial filter Vision Res 44 8 2004 839 848 (Pubitemid 38210280)
23. J.R. Landis, and G.G. Koch The measurement of observer agreement for categorical data Biometrics 33 1 1977 159 174 (Pubitemid 8054849)
24. J.S. Schuman, B. Horwitz, and N.T. Choplin A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension Arch Ophthalmol 115 7 1997 847 852
25. A.C. Viswanathan, D.P. Crabb, and A.I. McNaught Interobserver agreement on visual field progression in glaucoma: a comparison of methods Br J Ophthalmol 87 6 2003 726 730 (Pubitemid 36649225)
26. N.G. Strouthidis, A. Scott, N.M. Peter, and D.F. Garway-Heath Optic disc and visual field progression in ocular hypertensive subjects: detection rates, specificity, and agreement Invest Ophthalmol Vis Sci 47 7 2006 2904 2910 (Pubitemid 351639765)
27. M.C. Leske, A. Heijl, M. Hussein, B. Bengtsson, L. Hyman, and E. Komaroff Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial Arch Ophthalmol 121 1 2003 48 56 (Pubitemid 36401765)
28. A. Heijl, B. Bengtsson, L. Hyman, and M.C. Leske Natural history of open-angle glaucoma Ophthalmology 116 12 2009 2271 2276
29. J.E. Topper, and R.F. Brubaker Effects of timolol, epinephrine, and acetazolamide on aqueous flow during sleep Invest Ophthalmol Vis Sci 26 10 1985 1315 1319 (Pubitemid 15241053)
30. C.B. Toris, M.L. Gleason, C.B. Camras, and M.E. Yablonski Effects of brimonidine on aqueous humor dynamics in human eyes Arch Ophthalmol 113 12 1995 1514 1517
31. M.C. Leske, A.M. Connel, S.Y. Wu, L.G. Hyman, and A.P. Schachat Risk factors for open-angle glaucoma: the Barbados Eye Study Arch Ophthalmol 113 7 1995 918 924
32. J.M. Tielsch, J. Katz, A. Sommer, H.A. Quigley, and J.C. Javitt Hypertension, perfusion pressure, and primary open-angle glaucoma A population-based assessment Arch Ophthalmol 113 2 1995 216 221
33. L. Bonomi, G. Marchini, M. Marraffa, P. Bernardi, R. Morbio, and A. Varotto Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study Ophthalmology 107 7 2000 1287 1293
34. H.A. Quigley, S.K. West, J. Rodriguez, B. Munoz, R. Klein, and R. Snyder The prevalence of glaucoma in a population-based study of Hispanic subjects: Proyecto VER Arch Ophthalmol 119 12 2001 1819 1826 (Pubitemid 33139614)
35. M.C. Leske, A. Heijl, L. Hyman, B. Bengtsson, L. Dong, and Z. Yang Predictors of long-term progression in the Early Manifest Glaucoma Trial Ophthalmology 114 11 2007 1965 1972 (Pubitemid 350016362)
36. J.R. Nordlund, L.R. Pasquale, and A.L. Robin The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2% brimonidine Arch Ophthalmol 113 1 1995 77 83
37. S.S. Hayreh, P. Podhajsky, and M.B. Zimmerman Beta-blocker eyedrops and nocturnal arterial hypotension Am J Ophthalmol 128 3 1999 301 309 (Pubitemid 29413226)
38. L. Quaranta, F. Gandolfo, and R. Turano Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma Invest Ophthalmol Vis Sci 47 7 2006 2917 2923 (Pubitemid 351639767)
39. B. Reisberg, R. Doody, A. Stffler, F. Schmitt, S. Ferris, and H.J. Mbius Memantine in moderate-to-severe Alzheimer's disease N Engl J Med 348 14 2003 1333 1341 (Pubitemid 36384100)
40. G. Bensimon, L. Lacomblez, and V. Meininger A controlled trial of riluzole in amyotrophic lateral sclerosis ALS/Riluzole Study Group N Engl J Med 330 9 1994 585 591 (Pubitemid 24065791)
41. K.W. Muir, and P.A. Teal Why have neuro-protectants failed?: lessons learned from stroke trials J Neurol 252 9 2005 1011 1020 (Pubitemid 41355828)
42. H.V. Danesh-Meyer, and L.A. Levin Neuroprotection: Extrapolating from neurologic diseases to the eye Am J Ophthalmol 148 2 2009 186 191
43. R.N. Weinreb, and L.A. Levin Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 117 11 1999 1540 1544 (Pubitemid 29536483)
44. F.B. Wein, and L.A. Levin Current understanding of neuroprotection in glaucoma Curr Opin Ophthalmol 13 2 2002 61 67 (Pubitemid 34261263)
45. L.A. Kerrigan, D.J. Zack, H.A. Quigley, S.D. Smith, and M.E. Pease TUNEL-positive ganglion cells in human primary open-angle glaucoma Arch Ophthalmol 115 8 1997 1031 1035 (Pubitemid 27328493)
46. Allergan Inc Press Releases on Memantine Trials, Fourth Quarter Operating Results, Jan 30 2008 http://www.allergan.com/newsroom/index.htm Accessed: July 3, 2009
47. C. Maier, G.K. Steinberg, G.H. Sun, G.T. Zhi, and M. Maze Neuroprotection by the alpha 2-adrenoreceptor agonist dexmedetomidine in a focal model of cerebral ischemia Anesthesiology 79 2 1993 306 312 (Pubitemid 23224843)
48. L.A. Wheeler, R. Lai, and E. WoldeMussie From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury Eur J Ophthalmol 9 suppl 1 1999 S17 S21
49. E. WoldeMussie, M. Wijono, and D. Pow Localization of alpha 2 receptors in ocular tissues Vis Neurosci 24 5 2007 745 756 (Pubitemid 350073511)
50. T. Matsuo, and M.S. Cynader Localization of alpha-2 adrenergic receptors in the human eye Ophthalmic Res 24 4 1992 213 219
51. E. Yoles, L.A. Wheeler, and M. Schwartz Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration Invest Ophthalmol Vis Sci 40 1 1999 65 73 (Pubitemid 29029573)
52. E. WoldeMussie, G. Ruiz, M. Wijono, and L.A. Wheeler Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension Invest Ophthalmol Vis Sci 42 11 2001 2849 2855 (Pubitemid 33035282)
53. M. Hernndez, J.H. Urcola, and E. Vecino Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments Exp Eye Res 86 5 2008 798 806
54. H. Gao, X. Qiao, L.B. Cantor, and D. WuDunn Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells Arch Ophthalmol 120 6 2002 797 803 (Pubitemid 34620360)
55. R.K. Lai, T. Chun, D. Hasson, S. Lee, F. Mehrbod, and L. Wheeler Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat Vis Neurosci 19 2 2002 175 185 (Pubitemid 35230993)
56. C.-J. Dong, Y. Guo, P. Agey, L. Wheeler, and W.A. Hare Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity Invest Ophthalmol Vis Sci 49 10 2008 4515 4522
57. J. Burke, and M. Schwartz Preclinical evaluation of brimonidine Surv Ophthalmol 41 Suppl 1 1996 S9 S18
58. L. Wheeler, E. WoldeMussie, and R. Lai Role of alpha-2 agonists in neuroprotection Surv Ophthalmol 48 Suppl 1 2003 547 551
59. A.R. Kent, J.D. Nussdorf, R. David, F. Tyson, D. Small, and D. Fellows Vitreous concentration of topically applied brimonidine tartrate 0.2% Ophthalmology 108 4 2001 784 787 (Pubitemid 32238477)